skip to main content

brainstorm askiatroX medicines

simulations beta

loading page…

learn & practise

exams international doctors free questions Socratic Tutor rounds stat clinical connections academy journal tool guides

clinical reference

askiatroX knowledge centre medicines UK / NICE guidance international guidance calculators q&a library

trust & support

how it works methodology account & support frequently asked questions about us clinical safety consultancy

legal

mobile app · scan to download

Medicines fosaprepitant dimeglumineQuestion & answer

fosaprepitant dimeglumine · Medicine question

What should I report during the infusion?

iatroX medicinesPublished 20 August 2026Reviewed 20 August 2026

The answer

Answer

Immediately report breathing difficulty, flushing, hives, faintness, facial swelling or any burning, pain, redness or swelling around the cannula.

Sources for this answer

Fosaprepitant 150 mg powder for solution for infusionemc · SmPC Current selected SmPC · Version 1

Explore this learning need in CPDTake this topic to CPD, then choose your learning context and available question library.

The full medicine guide

fosaprepitant dimeglumine

Read the wider context, including uses, precautions and the sources behind this medicine guide.

Read the fosaprepitant dimeglumine guide

More questions about fosaprepitant dimeglumine

What is fosaprepitant dimeglumine used for?Is fosaprepitant dimeglumine chemotherapy?How is it given?Is it the same as aprepitant?Can children receive it?Does it affect contraception?

More clinical questions?

Explore the tools and reference material available on iatroX.

Explore askiatroX